Zhi Tong Cai Jing·2025-09-15 09:58Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection, which is developed in-house and targets upper gastrointestinal bleeding caused by various factors excluding tumors and esophageal or gastric variceal bleeding [1][3]. Group 1 - The approved indication for Famotidine Injection is for upper gastrointestinal bleeding due to peptic ulcers and other causes, excluding tumors and esophageal or gastric variceal bleeding [1]. - The total R&D investment for this drug by the company is approximately RMB 7.67 million (unaudited) as of August 2025 [2]. - The projected sales revenue for Famotidine Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 1.377 billion for the year 2024, according to IQVIA CHPA data [2]. Group 2 - The approval of this drug will further enrich the company's product line [3].